<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035082</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-4558</org_study_id>
    <secondary_id>U1111-1253-2577</secondary_id>
    <nct_id>NCT05035082</nct_id>
  </id_info>
  <brief_title>A Research Study Comparing RYBELSUS速 to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)</brief_title>
  <acronym>REALYSE</acronym>
  <official_title>REALYSE - Long-term Comparative Effectiveness of Once-daily Oral Semaglutide Versus Any Other Oral Glucose-lowering Medication in a Real-world Adult Population With Type 2 Diabetes on Metformin Monotherapy in US Based Health Care Systems - a Pragmatic Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is comparing the medicine RYBELSUS速 to other medicines in people with type 2&#xD;
      diabetes who need extra treatment. All medicines used in this study are tablets which lower&#xD;
      blood sugar in people with type 2 diabetes.&#xD;
&#xD;
      The purpose of the study is to see how well RYBELSUS速 is at lowering blood sugar compared to&#xD;
      other tablets when used in addition to metformin.&#xD;
&#xD;
      Participants doctor will give participants either RYBELSUS速 or any other blood sugar lowering&#xD;
      tablets - which treatment participants get is decided by chance.&#xD;
&#xD;
      The doctor treating participants diabetes will give participants a prescription for the&#xD;
      medicine and tell how to take it.&#xD;
&#xD;
      The study will last for about 2 years. Participants will have 3 planned visits with their&#xD;
      doctor which are part of the usual routine diabetes management: the first visit is when&#xD;
      participants are included in the study, the second visit is a 1-year follow-up visit, and the&#xD;
      last visit is a 2-year follow-up visit. In addition, the study personnel will contact&#xD;
      participants up to 3 times per year during this period and to follow-up on information from&#xD;
      participant doctors visits.&#xD;
&#xD;
      Participant will be asked to respond 3 times to 4 questionnaires via their personal&#xD;
      smartphone or tablet or paper if participant do not have access to one during the study.&#xD;
&#xD;
      All clinic visits are part of the usual routine diabetes management and are covered by&#xD;
      participants health insurance plan. The study team will collect information from these visits&#xD;
      recorded in the medical chart.&#xD;
&#xD;
      Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the&#xD;
      study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 21, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycosylated hemoglobin A1c (HbA1c)</measure>
    <time_frame>From randomization to year 1</time_frame>
    <description>percentage-points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>From randomization to year 2</time_frame>
    <description>percentage-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient achieving HbA1c below 7.0% (Yes /No)</measure>
    <time_frame>Year 1</time_frame>
    <description>Count of patient(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient achieving HbA1c below or equal to 6.5% (Yes/No)</measure>
    <time_frame>Year 1</time_frame>
    <description>Count of patient(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient achieving HbA1c below 7.0% or at least 1.0%-point reduction in HbA1c (Yes/No)</measure>
    <time_frame>From randomization to year 1</time_frame>
    <description>Count of patient(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient achieving greater than or equal to 5% reduction in body weight (Yes/No)</measure>
    <time_frame>From randomization to year 1</time_frame>
    <description>Count of patient(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient achieving individualized HbA1c target per Healthcare Effectiveness Data and Information Set (HEDIS) criteria (below 8.0% if age greater than or equal to 65 years or with defined comorbidities or otherwise below 7.0%) (Yes/No)</measure>
    <time_frame>Year 1</time_frame>
    <description>Count of patient(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient achieving HbA1c less than or equal to physician defined individualized target (Yes/No)</measure>
    <time_frame>Year 1</time_frame>
    <description>Count of patient(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in body weight (%)</measure>
    <time_frame>From randomization to year 1</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight (lbs)</measure>
    <time_frame>From randomization to year 1</time_frame>
    <description>Lbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment intensification (add-on) or change (switch)</measure>
    <time_frame>From randomization to year 2</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Treatment Satisfaction Questionnaire, change version (DTSQc), Relative treatment satisfaction total score</measure>
    <time_frame>Year 1</time_frame>
    <description>Score on a scale (The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) will be used to measure the change in patient satisfaction with their diabetes treatment. It consists of a six-item scale assessing treatment satisfaction and two items assessing perceived frequency of hyperglycaemia and hypoglycaemia. The DTSQc items are on a scale from 3 to -3. If they experience no change, then 0 is chosen. Higher score indicate higher satisfaction with their current treatment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1900</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>oral semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants are given tablets used in addition to metformin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other oral glucose lowering medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants are given tablets used in addition to metformin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Oral administration The doctor will give a prescription for the medicine and tell how to take it. The study will last for about 2 years.</description>
    <arm_group_label>oral semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral glucose-lowering medications (commercially available)</intervention_name>
    <description>Oral administration The doctor will give a prescription for the medicine and tell how to take it. The study will last for about 2 years.</description>
    <arm_group_label>other oral glucose lowering medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria&#xD;
&#xD;
          -  Treatment with metformin as monotherapy for a period of at least 90 days prior to&#xD;
             eligibility assessment.&#xD;
&#xD;
          -  Current member of a health plan which includes pharmacy benefits.&#xD;
&#xD;
          -  HbA1c greater than or equal to 7% within last 90 days prior to the day of screening or&#xD;
             to be taken before randomization.&#xD;
&#xD;
          -  Further intensification with an additional glucose-lowering oral agent including oral&#xD;
             semaglutide is indicated according to approved prescribing information to achieve&#xD;
             glycemic target at the discretion of the treating physician.&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             child-bearing potential and not using contraception.&#xD;
&#xD;
          -  Any disorder which in the investigator's or treating physician's opinion might&#xD;
             jeopardize patient's safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gillespie</city>
        <state>Illinois</state>
        <zip>62033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Garner</city>
        <state>North Carolina</state>
        <zip>27529</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-6810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

